GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% Solution is indicated as a replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients ≥2 years.
![GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% logo.](/content/experience-fragments/takeda/gammagard/us/en/hcp/header/master/_jcr_content/root/container_1325140548/container_6852551/container/image.coreimg.svg/1755842420057/logo-gammagard-white.svg){kind=logo}
GAMMAGARD LIQUID
PI Clinical Trial Results
PI=primary immunodeficiency.
Study Designs (Clinical Trials) PI
GAMMAGARD LIQUID was studied for IVIG use during a phase 3, multicenter clinical trial of 61 patients with PI. Patients in this trial received a total of 1,812 infusions. Infusions were administered at a dose of 300 to 600 mg/kg every 21 to 28 days for 12 months.1,2
GAMMAGARD LIQUID was studied for weekly subcutaneous IG (SCIG) use for treatment of PI in a prospective, open-label, non-controlled, multicenter study of 47 patients who received a total of 2,294 infusions. Patients who were receiving a minimum of 300 mg/kg of IG for at least 3 months were eligible for the study.1,3
- Patients in this trial received IVIG 10% every 3 or 4 weeks for 13 weeks before transitioning to SCIG1,3
- Patients received infusions of GAMMAGARD LIQUID SC 1 week after their last IVIG treatment. The SCIG treatment was dosed at 130% of the IVIG weekly equivalent dose for 12 weeks, followed by infusions at 137% of the IVIG weekly equivalent dose for 6 weeks1,3
The primary outcome measure for both the IVIG and SCIG trials was annual rate of acute serious bacterial infections (ASBIs); the annual rate definition was the mean number of ASBIs per patient per year.1-3
Sustained efficacy with intravenous immune globulin (IVIG) treatment
In the IV administration clinical trial, GAMMAGARD LIQUID provided sustained protection against infection with1,2:
0
zero validated acute serious bacterial infections (ASBIs)*†
0
zero hospitalizations secondary to validated bacterial infections
4
four validated other bacterial infections‡
*The rate of validated ASBIs (95% CI 0.000, 0.064; P<0.0001) was significantly lower than the rate of <1 per patient per year which was set by the FDA.
†Validated ASBIs include bacteremia/sepsis, bacterial meningitis, osteomyelitis/septic arthritis, bacterial pneumonia, and visceral abscess.
‡Validated other bacterial infections included 1 urinary tract infection, 1 gastroenteritis, and 2 otitis media. The rate of all clinically defined but nonvalidated infections was 3.4 infections per patient per year (n=61).
Sustained efficacy with subcutaneous IG (SCIG) treatment for PI
In the SC administration clinical trial, GAMMAGARD LIQUID provided sustained protection against infection with1,3:
0.067
annual rate of ASBIs
per patient per year was 0.067§
Three serious validated
bacterial pneumonia cases
0
zero infection-related hospitalizations per patient per year
4
four days of missed work/school or
days unable to perform normal activities
per patient per year||
Total number of subject years was 44
§The rate of validated ASBIs (0.067, upper 99% confidence limit of 0.133; P<0.0001) was significantly lower than the rate of <1 per patient per year which was set by the FDA.
∥95% CI, 2.5 to 6.1.
Stay up to date
Connect with us for more about GAMMAGARD LIQUID.
References:
- GAMMAGARD LIQUID. Prescribing Information. Takeda Pharmaceuticals U.S.A., Inc.; 2024.
- Church JA, Leibl H, Stein MR, et al. Efficacy, safety and tolerability of a new 10% liquid intravenous immune globulin [IGIV 10%] in patients with primary immunodeficiency. J Clin Immunol. 2006;26(4):388-395. doi:10.1007/s10875-006-9025-3
- Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011:31(3):323-331. doi:10.1007/s10875-011-9512-z